Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 1 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.


Player Avatar NHWeston102 (60.66) Submitted: 7/31/2012 8:16:24 PM : Underperform Start Price: $4.59 DNDN Score: -39.37

Dendreon appears rudderless. They are firing sales people, honking off physicians, and their provenage is just too expensive. Others are breaching their moat. Not looking good.

Featured Broker Partners